Between research and introduction to clinical routine—Experience with niraparib from the compassionate use program in Germany (NOGGO Register Analysis)

Abstract Purpose Ovarian cancer (OC) is frequently diagnosed at a late, advanced stage, resulting in poor survival outcomes. PARP inhibitors like niraparib have shown significant efficacy in high-grade OC, particularly in tumors with homologous recombination deficiency, including BRCA mutations. Thi...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Jacek P. Grabowski, Julia Welz, Sabine Heublein, Maja Krajewska, Jolijn D. Boer, Fabian Kraus, Tjadina Arndt, Nicolas Moosmann, Bernhard Heinrich, Tobias Engler, Saida Agabejli, Mustafa Celalettin Ugur, Ralf Witteler, Oliver Albrecht, Harald Müller-Huesmann, Gülten Oskay-Özcelik, Cristina Hettwer, Sabrina Kaiser, Elena Braicu, Jalid Sehouli
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Springer 2026-01-01
Edice:	Archives of Gynecology and Obstetrics
Témata:	PARP-Inhibitor CUP Clinical experience Ovarian cancer Real-world
On-line přístup:	https://doi.org/10.1007/s00404-025-08295-x
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!